These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 12047915

  • 1. Glucagon-like peptide-1 analogue LY315902: effect on intestinal motility and release of insulin and somatostatin.
    Näslund E, Skogar S, Efendic S, Hellström PM.
    Regul Pept; 2002 Jun 15; 106(1-3):89-95. PubMed ID: 12047915
    [Abstract] [Full Text] [Related]

  • 2. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin.
    Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellström PM.
    J Clin Invest; 1998 Aug 15; 102(4):764-74. PubMed ID: 9710445
    [Abstract] [Full Text] [Related]

  • 3. The inhibitory mechanism of GLP-1, but not glucagon, on fasted gut motility is dependent on the L-arginine/nitric oxide pathway.
    Tolessa T, Näslund E, Hellström PM.
    Regul Pept; 2001 Apr 02; 98(1-2):33-40. PubMed ID: 11179776
    [Abstract] [Full Text] [Related]

  • 4. GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat.
    Bozkurt A, Näslund E, Holst JJ, Hellström PM.
    Regul Pept; 2002 Jul 15; 107(1-3):129-35. PubMed ID: 12137975
    [Abstract] [Full Text] [Related]

  • 5. Receptor-mediated inhibition of small bowel migrating complex by GLP-1 analog ROSE-010 delivered via pulmonary and systemic routes in the conscious rat.
    Hellström PM, Smithson A, Stowell G, Greene S, Kenny E, Damico C, Leone-Bay A, Baughman R, Grant M, Richardson P.
    Regul Pept; 2012 Nov 10; 179(1-3):71-6. PubMed ID: 22960405
    [Abstract] [Full Text] [Related]

  • 6. Glucagon-like peptide-1 is a physiological incretin in rat.
    Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR.
    J Clin Invest; 1995 Jan 10; 95(1):417-21. PubMed ID: 7814643
    [Abstract] [Full Text] [Related]

  • 7. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
    Parkes DG, Pittner R, Jodka C, Smith P, Young A.
    Metabolism; 2001 May 10; 50(5):583-9. PubMed ID: 11319721
    [Abstract] [Full Text] [Related]

  • 8. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.
    Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Göke B.
    Gut; 2006 Feb 10; 55(2):243-51. PubMed ID: 15985560
    [Abstract] [Full Text] [Related]

  • 9. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
    Sandhu H, Wiesenthal SR, MacDonald PE, McCall RH, Tchipashvili V, Rashid S, Satkunarajah M, Irwin DM, Shi ZQ, Brubaker PL, Wheeler MB, Vranic M, Efendic S, Giacca A.
    Diabetes; 1999 May 10; 48(5):1045-53. PubMed ID: 10331409
    [Abstract] [Full Text] [Related]

  • 10. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F, Fehmann HC, Göke R, Göke B.
    Diabetes; 1995 Jan 10; 44(1):16-9. PubMed ID: 7813808
    [Abstract] [Full Text] [Related]

  • 11. Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line.
    Fehmann HC, Habener JF.
    FEBS Lett; 1991 Feb 25; 279(2):335-40. PubMed ID: 1672112
    [Abstract] [Full Text] [Related]

  • 12. Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide.
    Heller RS, Aponte GW.
    Am J Physiol; 1995 Dec 25; 269(6 Pt 1):G852-60. PubMed ID: 8572216
    [Abstract] [Full Text] [Related]

  • 13. Is glucagon-like peptide 1 an incretin hormone?
    Nauck MA.
    Diabetologia; 1999 Mar 25; 42(3):373-9. PubMed ID: 10096792
    [Abstract] [Full Text] [Related]

  • 14. Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum.
    Hansen L, Hartmann B, Mineo H, Holst JJ.
    Regul Pept; 2004 Apr 15; 118(1-2):11-8. PubMed ID: 14759551
    [Abstract] [Full Text] [Related]

  • 15. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, Efendic S.
    Diabetes Care; 1996 Aug 15; 19(8):857-63. PubMed ID: 8842604
    [Abstract] [Full Text] [Related]

  • 16. The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide.
    Wettergren A, Wøjdemann M, Holst JJ.
    Peptides; 1998 Aug 15; 19(5):877-82. PubMed ID: 9663453
    [Abstract] [Full Text] [Related]

  • 17. Interaction of glucagon-like peptide-1(7-36)amide and somatostatin-14 in RINm5F cells and in the perfused rat pancreas.
    Göke R, Fehmann HC, Richter G, Trautmann M, Göke B.
    Pancreas; 1989 Aug 15; 4(6):668-73. PubMed ID: 2573056
    [Abstract] [Full Text] [Related]

  • 18. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH.
    Am J Physiol; 1997 Nov 15; 273(5):E981-8. PubMed ID: 9374685
    [Abstract] [Full Text] [Related]

  • 19. Sympathetic pathways mediate GLP-1 actions in the gastrointestinal tract of the rat.
    Giralt M, Vergara P.
    Regul Pept; 1998 Apr 24; 74(1):19-25. PubMed ID: 9657354
    [Abstract] [Full Text] [Related]

  • 20. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
    Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA.
    Diabetologia; 2002 Oct 24; 45(10):1410-5. PubMed ID: 12378382
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.